olmesartan medoxomil has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Araújo, TE; Borba, PB; da Silva, AI; de Araújo Júnior, RF; de Araújo, AA; de Souza, FH; Nogueira, AC; Saldanha, TS | 1 |
1 review(s) available for olmesartan medoxomil and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
1 other study(ies) available for olmesartan medoxomil and Neoplasms
| Article | Year |
|---|---|
In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Diarrhea; Disease Models, Animal; Imidazoles; Inflammation; Interleukin-1beta; Intestinal Mucosa; Intestine, Small; Male; Methotrexate; Mucositis; Neoplasms; Olmesartan Medoxomil; Rats, Wistar; Sucrose; Tetrazoles; Tumor Necrosis Factor-alpha; Weight Loss | 2015 |